Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Common Equity (2023 - 2025)

Immunome's Common Equity history spans 3 years, with the latest figure at $634.3 million for Q4 2025.

  • For Q4 2025, Common Equity rose 250.15% year-over-year to $634.3 million; the TTM value through Dec 2025 reached $634.3 million, up 250.15%, while the annual FY2025 figure was $634.3 million, 250.15% up from the prior year.
  • Common Equity reached $634.3 million in Q4 2025 per IMNM's latest filing, up from $263.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $634.3 million in Q4 2025 to a low of $6.1 million in Q3 2023.
  • Average Common Equity over 3 years is $213.3 million, with a median of $234.4 million recorded in 2024.
  • Peak YoY movement for Common Equity: soared 3436.97% in 2024, then increased 6.08% in 2025.
  • A 3-year view of Common Equity shows it stood at $119.9 million in 2023, then soared by 51.12% to $181.2 million in 2024, then skyrocketed by 250.15% to $634.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Common Equity are $634.3 million (Q4 2025), $263.9 million (Q3 2025), and $269.3 million (Q2 2025).